Associated Papers
Tropomyosin 3 Gene Fusions in Cancers: From Mechanisms to Treatments-A Comprehensive Review.
Chen A et al.
Cancer Medicine, 2025
TPM3-NTRK1 fusion confers resistance to osimertinib in lung adenocarcinoma: a model in a continuous cell line.
Cao F et al.
Human Cell, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
A comprehensive database for identifying and interpreting ctDNA driver genes and variants in cancer.
Wang Y et al.
Scientific Data, 2025
Recent Applications of In Silico Approaches for Studying Receptor Mutations Associated with Human Pathologies.
Pappalardo M et al.
Molecules (basel, Switzerland), 2024
A Novel Oncogenic and Drug-Sensitive KIF5B-NTRK1 Fusion in Lung Adenocarcinoma.
Li H et al.
Current Oncology (toronto, Ont.), 2024
ERK signaling promotes resistance to TRK kinase inhibition in NTRK fusion-driven glioma mouse models.
Schmid S et al.
Cell Reports, 2024
BPI-28592 as a novel second generation inhibitor for NTRK fusion tumors.
Sheng J et al.
Npj Precision Oncology, 2024
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.
Roa P et al.
British Journal of Cancer, 2024
A recurrent NTRK1 tyrosine kinase domain mutation pair is characteristic in a subset of dedifferentiated liposarcomas.
Lippai Z et al.
European Journal of Cancer (oxford, England : 1990), 2024
Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in China.
Xu Y et al.
Npj Precision Oncology, 2023
Development of a Cell Line Containing the Chimeric ETV6-NTRK3 Gene. The Search for Mutations of the Tyrosine Kinase Chimeric Domain That Cause Resistance to Larotrectinib.
Boyarskikh UA et al.
Bulletin of Experimental Biology and Medicine, 2023
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.
Wang Z et al.
Molecular Biomedicine, 2022
Targeting Gatekeeper Mutations for Kinase Drug Discovery.
Zhou Y et al.
Journal of Medicinal Chemistry, 2022
JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo.
Wang J et al.
Molecules (basel, Switzerland), 2022
Exploring the kinase-inhibitor fragment interaction space facilitates the discovery of kinase inhibitor overcoming resistance by mutations.
Wang ZZ et al.
Briefings in Bioinformatics, 2022
Conformational adjustment overcomes multiple drug-resistance mutants of tropomyosin receptor kinase.
Mei LC et al.
European Journal of Medicinal Chemistry, 2022
NTRK-fusions in pediatric thyroid tumors: Current state and future perspectives.
Casado-Medrano V et al.
Cancer Genetics, 2022
Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance.
Wang Z et al.
Journal of Medicinal Chemistry, 2022
Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.
Koga T et al.
Cancer Science, 2022
Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib.
Wu WC et al.
Frontiers in Oncology, 2022
Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations.
Murray BW et al.
Molecular Cancer Therapeutics, 2021
Discovery of Next-Generation Tropomyosin Receptor Kinase Inhibitors for Combating Multiple Resistance Associated with Protein Mutation.
Zhuo LS et al.
Journal of Medicinal Chemistry, 2021
Mechanisms of targeted therapy resistance in a pediatric glioma driven by ETV6-NTRK3 fusion.
Keddy C et al.
Cold Spring Harbor Molecular Case Studies, 2021
Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases.
Moccia M et al.
Scientific Reports, 2021
Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy.
Picco G et al.
Cancer Discovery, 2021
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
Mizuta H et al.
Nature Communications, 2021
Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature.
Gupta M et al.
Journal of the National Comprehensive Cancer Network : Jnccn, 2021
TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors.
Cocco E et al.
Cancer Discovery, 2021
NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.
Somwar R et al.
Communications Biology, 2020
[Chinese Expert Consensus on Next Generation Sequencing Diagnosis for Non-small Cell Lung Cancer (2020 Edition)].
Unknown Author
Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer, 2020
Synthetic inhibitor leads of human tropomyosin receptor kinase A (hTrkA).
Subramanian G et al.
Rsc Medicinal Chemistry, 2020
Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer.
López-Cortés A et al.
The Pharmacogenomics Journal, 2020
Roles of TrkC Signaling in the Regulation of Tumorigenicity and Metastasis of Cancer.
Jin W
Cancers, 2020
Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion.
Chu QS
Therapeutic Advances in Medical Oncology, 2020
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Katayama R et al.
Nature Communications, 2019
Protein Allostery in Rational Drug Design.
Kinoshita T
Advances in Experimental Medicine and Biology, 2019
Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion-Positive Tumor Cells in a Brain Metastasis Model.
Nishiyama A et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018
Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling.
Oldrini B et al.
Nature Communications, 2018
Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.
Konicek BW et al.
Oncotarget, 2018
Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics.
Okamura R et al.
Jco Precision Oncology, 2018
Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor.
Alvarez-Breckenridge C et al.
Npj Precision Oncology, 2017
Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.
Russo M et al.
Cancer Discovery, 2016